How Real-Time Location Data and AI Improve Utilization of Clinic Exam Rooms with Isobel Handler Kontakt io

Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets.  This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing a potentially disease-modifying treatment that would be given locally for orthopedic painful conditions. The concept is that human platelets are wonderful at eliciting healing in a normal physiological setting. Why can't we create a biologic product that, when given locally, emulates that same functionality where the imbalance has gone bad?"   "I'd call this version one of the first generation of platelet- and plasma-derived biologic therapy. So it runs in the same path. It goes to the same regulators, but it's not so much an evolution as it is a parallel path."   "So chronic sciatica, or when you get fancy with medical terminology, chronic lumbosacral radiculopathy, is basically, and we'll try to keep this PG. I'm a bit Australian and tend to get a little fruity with my language. When you do something silly- wake up, twist, lift the weight badly, bend over- you can pretty easily piss off your spinal nerves, which are the small nerves that come out of your spine and then innervate your extremities."  #ConsanoBIo #Sciatica #BackPain #ChronicPaint #PainTreatment #NonOpioids #LumbosacralRadiculopathy #LSR  #ChronicPain #Biotech #ClinicalTrials #PainManagement #Orthobiologics #DrugDevelopment #HealthcareInnovation #Neurology #MedicalResearch consanobio.com Listen to the podcast here

Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets.  This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing a potentially disease-modifying treatment that would be given locally for orthopedic painful conditions. The concept is that human platelets are wonderful at eliciting healing in a normal physiological setting. Why can't we create a biologic product that, when given locally, emulates that same functionality where the imbalance has gone bad?"   "I'd call this version one of the first generation of platelet- and plasma-derived biologic therapy. So it runs in the same path. It goes to the same regulators, but it's not so much an evolution as it is a parallel path."   "So chronic sciatica, or when you get fancy with medical terminology, chronic lumbosacral radiculopathy, is basically, and we'll try to keep this PG. I'm a bit Australian and tend to get a little fruity with my language. When you do something silly- wake up, twist, lift the weight badly, bend over- you can pretty easily piss off your spinal nerves, which are the small nerves that come out of your spine and then innervate your extremities."  #ConsanoBIo #Sciatica #BackPain #ChronicPaint #PainTreatment #NonOpioids #LumbosacralRadiculopathy #LSR  #ChronicPain #Biotech #ClinicalTrials #PainManagement #Orthobiologics #DrugDevelopment #HealthcareInnovation #Neurology #MedicalResearch consanobio.com Download the transcript here

Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization.  By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients and reduce clinician burnout.    Isobel explains, "Kontakt.io uses real-time location data, often referred to as RTLS, to improve hospital and clinic operations. We'll talk a lot today about our ambulatory use cases focused on patient access. Still, we also have solutions for inpatient flow, length-of-stay reduction, staff safety, asset tracking, and much more that I won't list. But I think what's really exciting about Kontakt.io is you'll see a lot of RTLS companies in the industry who have built solutions that provide really beautiful blue dots on a map. But at Kontakt.io, we see the opportunity to leverage RTLS beyond that blue dot to produce a set of data that's really well trained and tuned to feed AI models. RTLS data is plentiful, it's machine-generated, it's unbiased, and it doesn't require a human being with a clinical license to enter it. So it produces a lot of really useful information for AI models that are solving some of the top health system problems out there today."   "I think it's an environment that's really ripe for some more data to help us understand what's going on in the exam room, as you pointed out. But a shocking statistic is that most exam rooms are only utilized 33% of the time during standard business hours, which feels incredibly low the first time you hear it. But if you think through the logic of how we get to that utilization rate, the performance actually seems quite intuitive." #KontaktIO #IntelligentOrchestration #HospitalOperations #HealthcareAI #PatientAccess #DigitalHealth #HealthcareInnovation #RTLS #AmbulatoryCare #HealthIT #ClinicianBurnout #HealthcareLeadership  Kontakt.io Listen to the podcast here

Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization.  By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients and reduce clinician burnout.    Isobel explains, "Kontakt.io uses real-time location data, often referred to as RTLS, to improve hospital and clinic operations. We'll talk a lot today about our ambulatory use cases focused on patient access. Still, we also have solutions for inpatient flow, length-of-stay reduction, staff safety, asset tracking, and much more that I won't list. But I think what's really exciting about Kontakt.io is you'll see a lot of RTLS companies in the industry who have built solutions that provide really beautiful blue dots on a map. But at Kontakt.io, we see the opportunity to leverage RTLS beyond that blue dot to produce a set of data that's really well trained and tuned to feed AI models. RTLS data is plentiful, it's machine-generated, it's unbiased, and it doesn't require a human being with a clinical license to enter it. So it produces a lot of really useful information for AI models that are solving some of the top health system problems out there today."   "I think it's an environment that's really ripe for some more data to help us understand what's going on in the exam room, as you pointed out. But a shocking statistic is that most exam rooms are only utilized 33% of the time during standard business hours, which feels incredibly low the first time you hear it. But if you think through the logic of how we get to that utilization rate, the performance actually seems quite intuitive." #KontaktIO #IntelligentOrchestration #HospitalOperations #HealthcareAI #PatientAccess #DigitalHealth #HealthcareInnovation #RTLS #AmbulatoryCare #HealthIT #ClinicianBurnout #HealthcareLeadership  Kontakt.io Download the transcript here  

Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure patients. Steffen-Sebastian explains, "So what we would consider resistance arteries is anything between the capillary level, which would be 10 micrometers, up to, let's say, a few hundred micrometers. And 300 micrometers is the thickness of a blonde hair. That's kind of what we're talking about here. And everything else, and what I talk about in function is what I said before: they can change their diameter. They can open up or close, which large arteries can not do. They are stiff as a garden hose. They are conduits with arteries. They are made to conduct blood at the lowest resistance possible, whereas the small resistance arteries are made to change resistance and regulate flow and pressure."   "As I said, these small resistance arteries and capillaries are everywhere. Every organ has them. And if you compromise the function of those resistance arteries, you compromise blood flow to the capillaries, which actually means that the capillaries don't get enough oxygen. They cannot transport CO2 away from the tissues. They don't get enough nutrients and so on, which then leads to functional damage, which is number one." "And if it persists, if the problem persists, it can also lead to structural damage, which we can actually see. You mentioned the heart. The heart can deal with it, and also the brain can deal with reductions in that flow to a certain extent. But if the reduction in blood flow exceeds a certain limit, you get structural damage. And we see that structural damage. And we call them infarctions in the heart, but also in the brain, which is a stroke." #QanatPharma #VascularBiology #MicrovascularHealth #DrugDiscovery #HeartFailure #CognitiveImpairment #BiotechInnovation #PrecisionMedicine #AIinDrugDiscovery#Microvascular #Neurology #DrugRepurposing #Cardiology #MedicalResearch #ClinicalTrials #Hypertension qanatpharma.com Listen to the podcast here

Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure patients. Steffen-Sebastian explains, "So what we would consider resistance arteries is anything between the capillary level, which would be 10 micrometers, up to, let's say, a few hundred micrometers. And 300 micrometers is the thickness of a blonde hair. That's kind of what we're talking about here. And everything else, and what I talk about in function is what I said before: they can change their diameter. They can open up or close, which large arteries can not do. They are stiff as a garden hose. They are conduits with arteries. They are made to conduct blood at the lowest resistance possible, whereas the small resistance arteries are made to change resistance and regulate flow and pressure."   "As I said, these small resistance arteries and capillaries are everywhere. Every organ has them. And if you compromise the function of those resistance arteries, you compromise blood flow to the capillaries, which actually means that the capillaries don't get enough oxygen. They cannot transport CO2 away from the tissues. They don't get enough nutrients and so on, which then leads to functional damage, which is number one." "And if it persists, if the problem persists, it can also lead to structural damage, which we can actually see. You mentioned the heart. The heart can deal with it, and also the brain can deal with reductions in that flow to a certain extent. But if the reduction in blood flow exceeds a certain limit, you get structural damage. And we see that structural damage. And we call them infarctions in the heart, but also in the brain, which is a stroke." #QanatPharma #VascularBiology #MicrovascularHealth #DrugDiscovery #HeartFailure #CognitiveImpairment #BiotechInnovation #PrecisionMedicine #AIinDrugDiscovery#Microvascular #Neurology #DrugRepurposing #Cardiology #MedicalResearch #ClinicalTrials #Hypertension qanatpharma.com Download the transcript here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Listen to the podcast here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Download the transcript here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Download the transcript here